ArticleFrontiers in pharmacology2021
β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Beta-Caryophyllene Attenuates the In Vitro Oxidation of LDL.Biomedicines · 2026Article
- Essential oil from Eugenia stipitata McVaugh leaves exhibits antinociceptive effect via opioid receptor activation.Inflammopharmacology · 2026Article
- Brain CB2 receptor: a new target in medication development for treating opioid use disorder in rodents.Molecular psychiatry · 2026Article
- Acute or Chronic β-Caryophyllene Systemic Administration in Healthy Adult Male Mice Does Not Modulate Anxiety-Like Extinction Behavior Induced by Subsequent Re-Exposure to 3D Maze.Fundamental & clinical pharmacology · 2025Article
- Investigation of the protective effect of beta caryophyllene against indomethacin-induced gastric ulcer in rats: in vivo and in vitro study.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Advancing Brain Health Naturally: β-Caryophyllene and Xanthohumol as Neuroprotective Agents.Molecules (Basel, Switzerland) · 2025Review
- Novel potential pharmacological approaches in treating eating disorders comorbid with substance use disorders.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- The analgesic and anti-inflammatory effects of a combined preparation based on the blunt-nosed viper's venom and oregano essential oil.The Korean journal of pain · 2025Article
- Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation.Archives of pharmacal research · 2025Review
- β-caryophyllene inhibits heroin self-administration, but does not alter opioid-induced antinociception in rodents.Neuropharmacology · 2024Article
- Optical Intracranial Self-Stimulation (oICSS): A New Behavioral Model for Studying Drug Reward and Aversion in Rodents.International journal of molecular sciences · 2024Review
- Effects of β -caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction.Current neuropharmacology · 2023Article
- β-Caryophyllene Ameliorates Cyclophosphamide Induced Cardiac Injury: The Association of TLR4/NFκB and Nrf2/HO1/NQO1 Pathways.Journal of cardiovascular development and disease · 2022Article
- New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.International journal of molecular sciences · 2022Review
- Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders.Frontiers in psychiatry · 2022Review
- Cannabinoid CBFrontiers in pharmacology · 2022Article
- New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction. However, it is unclear whether β-caryophyllene (BCP), a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine (METH) abuse and dependence. In this study, we used animal models of self-administration, electrical brain-stimulation reward (BSR) and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.